Literature DB >> 20657552

Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium.

Ayuko Sato1, Ikuko Torii, Yoshihiro Okamura, Tadashi Yamamoto, Takashi Nishigami, Tatsuki R Kataoka, Misa Song, Seiki Hasegawa, Takashi Nakano, Toshiaki Kamei, Tohru Tsujimura.   

Abstract

Malignant pleural mesothelioma is a refractory tumor with poor prognosis associated with asbestos exposure. Pleural effusion is frequently observed in patients with malignant pleural mesothelioma, and cytological analysis is effective to detect malignant pleural mesothelioma. However, cytological discrimination between malignant pleural mesothelioma and reactive mesothelium is often difficult. Increased expression of CD146, a cell adhesion molecule, has been reported to be closely associated with an advanced stage of malignant melanoma, prostate cancer, and ovarian cancer. In this study, to evaluate the diagnostic utility of CD146 for discrimination between malignant pleural mesothelioma and reactive mesothelium, we examined immunocytochemical expression of CD146 in malignant pleural mesothelioma and reactive mesothelium using two clones of CD146 antibody, OJ79 and EPR3208, on smear specimens of effusion fluids. Immunocytochemical stains were semiquantitatively scored on the basis of immunostaining intensity (0, negative; 1, weak positive; 2, moderate positive; and 3, strong positive). CD146 expression was detected in 15 of 16 malignant pleural mesothelioma with median immunostaining score of 3 by OJ79, and in 19 of 21 malignant pleural mesothelioma with median immunostaining score of 2 by EPR3208. Strong immunoreactivity of CD146 was observed at the apposing surfaces of cell-cell interactions on the plasma membrane of mesothelioma cells. In addition, one OJ79-negative case of malignant pleural mesothelioma was positive for CD146 by EPR3208 and two EPR3208-negative cases of malignant pleural mesothelioma were CD146 positive by OJ79, showing that all 23 malignant pleural mesothelioma cases were positive for CD146 by either OJ79 or EPR3208. On the other hand, CD146 expression was undetectable in all reactive mesothelium cases by OJ79 and EPR3208. The sensitivity of OJ79 and EPR3208 was 94 and 90%, respectively, and the specificity was 100% for both clones. We propose that CD146 is a sensitive and specific immunocytochemical marker enabling differential diagnosis of malignant pleural mesothelioma from reactive mesothelium.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20657552     DOI: 10.1038/modpathol.2010.134

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  17 in total

1.  Evaluation of the sensitivity and specificity of immunohistochemical markers in the differential diagnosis of effusion cytology.

Authors:  Zahraa Mohammed Yahya; Hussam Hasson Ali; Haider Ghazi Hussein
Journal:  Oman Med J       Date:  2013-11

2.  CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer.

Authors:  Qiqun Zeng; Weidong Li; Di Lu; Zhenzhen Wu; Hongxia Duan; Yongting Luo; Jing Feng; Dongling Yang; Li Fu; Xiyun Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-30       Impact factor: 11.205

3.  Capture of mesothelioma cells with 'universal' CTC-chip.

Authors:  Kazue Yoneda; Yasuhiro Chikaishi; Taiji Kuwata; Takashi Ohnaga; Fumihiro Tanaka
Journal:  Oncol Lett       Date:  2017-12-14       Impact factor: 2.967

4.  β-catenin expression in benign and malignant pleural disorders.

Authors:  Waseem Anani; Richard Bruggeman; Dani S Zander
Journal:  Int J Clin Exp Pathol       Date:  2011-10-30

Review 5.  Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review.

Authors:  Rossella Bruno; Greta Alì; Gabriella Fontanini
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

6.  BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.

Authors:  Marta Cigognetti; Silvia Lonardi; Simona Fisogni; Piera Balzarini; Vilma Pellegrini; Andrea Tironi; Luisa Bercich; Mattia Bugatti; Giulio Rossi; Bruno Murer; Mattia Barbareschi; Silvia Giuliani; Alberto Cavazza; Gianpietro Marchetti; William Vermi; Fabio Facchetti
Journal:  Mod Pathol       Date:  2015-05-29       Impact factor: 7.842

Review 7.  Pathological and molecular biological approaches to early mesothelioma.

Authors:  Tohru Tsujimura; Ikuko Torii; Ayuko Sato; Misa Song; Kazuya Fukuoka; Seiki Hasegawa; Takashi Nakano
Journal:  Int J Clin Oncol       Date:  2012-01-12       Impact factor: 3.402

Review 8.  Practical approaches to diagnose and treat for T0 malignant pleural mesothelioma: a proposal for diagnostic total parietal pleurectomy.

Authors:  Seiki Hasegawa; Nobuyuki Kondo; Seiji Matsumoto; Teruhisa Takuwa; Masaki Hashimoto; Hayato Orui; Shunichi Fukuda; Kazue Yoneda; Yoshitomo Okumura; Noriaki Tsubota; Kazuya Fukuoka; Ikuko Torii; Tohru Tsujimura; Takashi Nakano
Journal:  Int J Clin Oncol       Date:  2012-01-12       Impact factor: 3.402

9.  CD146 promotes metastasis and predicts poor prognosis of hepatocellular carcinoma.

Authors:  Guoqing Jiang; Long Zhang; Qin Zhu; Dousheng Bai; Chuanyong Zhang; Xuehao Wang
Journal:  J Exp Clin Cancer Res       Date:  2016-02-29

Review 10.  Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology.

Authors:  Anders Hjerpe; Valeria Ascoli; Carlos Bedrossian; Mathilde Boon; Jenette Creaney; Ben Davidson; Annika Dejmek; Katalin Dobra; Ambrogio Fassina; Andrew Field; Pinar Firat; Toshiaki Kamei; Tadao Kobayashi; Claire W Michael; Sevgen Önder; Amanda Segal; Philippe Vielh
Journal:  Cytojournal       Date:  2015-11-30       Impact factor: 2.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.